Role of proliferation in HER2 status predicted response to doxorubicin

Manuela Campiglio, Giulia Somenzi, Clelia Olgiati, Giovanni Beretta, Andrea Balsari, Nadia Zaffaroni, Pinuccia Valagussa, Sylvie Ménard

Research output: Contribution to journalArticle

Abstract

The role of HER2 in predicting response to doxorubicin (DXR) therapy in breast cancer was evaluated in vivo in a series of breast carcinomas from 220 patients with tumors larger than 2.5 cm and treated with 3 cycles of DXR (75 mg/m2) as neoadjuvant chemotherapy. Patients with HER2-positive tumors were more frequently responsive to DXR treatment compared with HER2-negative patients (p = 0.05; Mantel-Haenszel X2 = 0.009). Progesterone receptor (PgR) negativity, but not mutated p53, was also associated with response to DXR (p = 0.05; Mantel-Haenszel X2 = 0.004). Further analysis of those correlations using breast carcinoma cell lines characterized for different biologic parameters revealed a trend between HER2 positivity/PgR negativity and greater DXR sensitivity, but the strongest direct correlation was found between the proliferation rate and sensitivity to DXR (r = 0.82, p = 0.00009). Neither p53 nor the DXR target molecule topoisomerase-II-α was significantly associated with in vitro sensitivity to DXR. Thus, whereas data showed that the major biologic parameter associated with in vitro response to DXR in breast cancer cells appears to be the tumor proliferation rate, HER2 expression together with PgR negativity may serve as the counterpart of the proliferation marker in predicting the in vivo response to DXR.

Original languageEnglish
Pages (from-to)568-573
Number of pages6
JournalInternational Journal of Cancer
Volume105
Issue number4
DOIs
Publication statusPublished - Jul 1 2003

Fingerprint

Doxorubicin
Progesterone Receptors
Breast Neoplasms
Neoplasms
Type II DNA Topoisomerase
Drug Therapy
Cell Line
Therapeutics

Keywords

  • Breast carcinoma
  • Doxorubicin
  • HER2
  • Tumor cells proliferation
  • Tumor response prediction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Campiglio, M., Somenzi, G., Olgiati, C., Beretta, G., Balsari, A., Zaffaroni, N., ... Ménard, S. (2003). Role of proliferation in HER2 status predicted response to doxorubicin. International Journal of Cancer, 105(4), 568-573. https://doi.org/10.1002/ijc.11113

Role of proliferation in HER2 status predicted response to doxorubicin. / Campiglio, Manuela; Somenzi, Giulia; Olgiati, Clelia; Beretta, Giovanni; Balsari, Andrea; Zaffaroni, Nadia; Valagussa, Pinuccia; Ménard, Sylvie.

In: International Journal of Cancer, Vol. 105, No. 4, 01.07.2003, p. 568-573.

Research output: Contribution to journalArticle

Campiglio, M, Somenzi, G, Olgiati, C, Beretta, G, Balsari, A, Zaffaroni, N, Valagussa, P & Ménard, S 2003, 'Role of proliferation in HER2 status predicted response to doxorubicin', International Journal of Cancer, vol. 105, no. 4, pp. 568-573. https://doi.org/10.1002/ijc.11113
Campiglio, Manuela ; Somenzi, Giulia ; Olgiati, Clelia ; Beretta, Giovanni ; Balsari, Andrea ; Zaffaroni, Nadia ; Valagussa, Pinuccia ; Ménard, Sylvie. / Role of proliferation in HER2 status predicted response to doxorubicin. In: International Journal of Cancer. 2003 ; Vol. 105, No. 4. pp. 568-573.
@article{f6bec025f65c4f60829065c3f1c1495b,
title = "Role of proliferation in HER2 status predicted response to doxorubicin",
abstract = "The role of HER2 in predicting response to doxorubicin (DXR) therapy in breast cancer was evaluated in vivo in a series of breast carcinomas from 220 patients with tumors larger than 2.5 cm and treated with 3 cycles of DXR (75 mg/m2) as neoadjuvant chemotherapy. Patients with HER2-positive tumors were more frequently responsive to DXR treatment compared with HER2-negative patients (p = 0.05; Mantel-Haenszel X2 = 0.009). Progesterone receptor (PgR) negativity, but not mutated p53, was also associated with response to DXR (p = 0.05; Mantel-Haenszel X2 = 0.004). Further analysis of those correlations using breast carcinoma cell lines characterized for different biologic parameters revealed a trend between HER2 positivity/PgR negativity and greater DXR sensitivity, but the strongest direct correlation was found between the proliferation rate and sensitivity to DXR (r = 0.82, p = 0.00009). Neither p53 nor the DXR target molecule topoisomerase-II-α was significantly associated with in vitro sensitivity to DXR. Thus, whereas data showed that the major biologic parameter associated with in vitro response to DXR in breast cancer cells appears to be the tumor proliferation rate, HER2 expression together with PgR negativity may serve as the counterpart of the proliferation marker in predicting the in vivo response to DXR.",
keywords = "Breast carcinoma, Doxorubicin, HER2, Tumor cells proliferation, Tumor response prediction",
author = "Manuela Campiglio and Giulia Somenzi and Clelia Olgiati and Giovanni Beretta and Andrea Balsari and Nadia Zaffaroni and Pinuccia Valagussa and Sylvie M{\'e}nard",
year = "2003",
month = "7",
day = "1",
doi = "10.1002/ijc.11113",
language = "English",
volume = "105",
pages = "568--573",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Role of proliferation in HER2 status predicted response to doxorubicin

AU - Campiglio, Manuela

AU - Somenzi, Giulia

AU - Olgiati, Clelia

AU - Beretta, Giovanni

AU - Balsari, Andrea

AU - Zaffaroni, Nadia

AU - Valagussa, Pinuccia

AU - Ménard, Sylvie

PY - 2003/7/1

Y1 - 2003/7/1

N2 - The role of HER2 in predicting response to doxorubicin (DXR) therapy in breast cancer was evaluated in vivo in a series of breast carcinomas from 220 patients with tumors larger than 2.5 cm and treated with 3 cycles of DXR (75 mg/m2) as neoadjuvant chemotherapy. Patients with HER2-positive tumors were more frequently responsive to DXR treatment compared with HER2-negative patients (p = 0.05; Mantel-Haenszel X2 = 0.009). Progesterone receptor (PgR) negativity, but not mutated p53, was also associated with response to DXR (p = 0.05; Mantel-Haenszel X2 = 0.004). Further analysis of those correlations using breast carcinoma cell lines characterized for different biologic parameters revealed a trend between HER2 positivity/PgR negativity and greater DXR sensitivity, but the strongest direct correlation was found between the proliferation rate and sensitivity to DXR (r = 0.82, p = 0.00009). Neither p53 nor the DXR target molecule topoisomerase-II-α was significantly associated with in vitro sensitivity to DXR. Thus, whereas data showed that the major biologic parameter associated with in vitro response to DXR in breast cancer cells appears to be the tumor proliferation rate, HER2 expression together with PgR negativity may serve as the counterpart of the proliferation marker in predicting the in vivo response to DXR.

AB - The role of HER2 in predicting response to doxorubicin (DXR) therapy in breast cancer was evaluated in vivo in a series of breast carcinomas from 220 patients with tumors larger than 2.5 cm and treated with 3 cycles of DXR (75 mg/m2) as neoadjuvant chemotherapy. Patients with HER2-positive tumors were more frequently responsive to DXR treatment compared with HER2-negative patients (p = 0.05; Mantel-Haenszel X2 = 0.009). Progesterone receptor (PgR) negativity, but not mutated p53, was also associated with response to DXR (p = 0.05; Mantel-Haenszel X2 = 0.004). Further analysis of those correlations using breast carcinoma cell lines characterized for different biologic parameters revealed a trend between HER2 positivity/PgR negativity and greater DXR sensitivity, but the strongest direct correlation was found between the proliferation rate and sensitivity to DXR (r = 0.82, p = 0.00009). Neither p53 nor the DXR target molecule topoisomerase-II-α was significantly associated with in vitro sensitivity to DXR. Thus, whereas data showed that the major biologic parameter associated with in vitro response to DXR in breast cancer cells appears to be the tumor proliferation rate, HER2 expression together with PgR negativity may serve as the counterpart of the proliferation marker in predicting the in vivo response to DXR.

KW - Breast carcinoma

KW - Doxorubicin

KW - HER2

KW - Tumor cells proliferation

KW - Tumor response prediction

UR - http://www.scopus.com/inward/record.url?scp=0038612855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038612855&partnerID=8YFLogxK

U2 - 10.1002/ijc.11113

DO - 10.1002/ijc.11113

M3 - Article

C2 - 12712452

AN - SCOPUS:0038612855

VL - 105

SP - 568

EP - 573

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -